<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01301703</url>
  </required_header>
  <id_info>
    <org_study_id>0068-09</org_study_id>
    <nct_id>NCT01301703</nct_id>
  </id_info>
  <brief_title>Vaccination Against Pertussis, Tetanus and Diphtheria in Patients Suffering From Rheumatoid Arthritis</brief_title>
  <official_title>The Efficacy and Safety of Vaccination Against Pertussis. Tetanus and Diphtheria in Patients Suffering From Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tel-Aviv Sourasky Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tel-Aviv Sourasky Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pertussis is an acute respiratory infection caused by Bordetella pertussis. Rates of recent&#xD;
      B. pertussis infection between 8%--26% have been reported among adults with cough illness of&#xD;
      at least 5 days duration who sought medical care. The CDC recommends vaccinating patients&#xD;
      aged 15 to 64 years old, once in 10 years. Although acellular vaccines such as BOOSTRIX have&#xD;
      been evaluated in healthy population, the safety and efficacy of this vaccine in patients&#xD;
      suffering from rheumatic diseases have not been established.&#xD;
&#xD;
      Study population : 50 Rheumatoid Arthritis (RA) patients and 5 healthy controls&#xD;
&#xD;
      Evaluation : the evaluation will be performed on week 0 and 4-6 weeks later. In terms of&#xD;
      safety, the patients will be evaluated according to the Disease Activity Index (DAS). Blood&#xD;
      will be drawn at each visit at tested for humoral response to tetanus and pertussis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>March 2011</start_date>
  <completion_date type="Anticipated">February 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunogenicity of Tdap in patients suffering from rheumatoid arthritis</measure>
    <time_frame>4-6 weeks after vaccination</time_frame>
    <description>Geometric mean titers and individual responses to components of pertussis, tetanus and diphtheria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of Tdap vaccine in RA patients</measure>
    <time_frame>4-6 weeks after vaccination</time_frame>
    <description>Safety will be evaluated using the disease activity score (DAS) at baseline and 4-6 weeks later</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Tdap vaccination</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients and controls will be vaccinated with BOOSTRIX (Tdap vaccine)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed)</intervention_name>
    <description>a single 0.5-mL intramuscular injection into the deltoid muscle of the upper arm</description>
    <arm_group_label>Tdap vaccination</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients suffering from RA&#xD;
&#xD;
          -  Aged 18 to 64 years old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active disease requiring a change in drug regimen&#xD;
&#xD;
          -  Known allergy to vaccine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ori Elkayam, M.D</last_name>
    <phone>97236973668</phone>
    <email>orie@tasmc.health.gov.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Rheumatology, Tel Aviv Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <contact>
      <last_name>Ori Elkayam, M.D</last_name>
      <phone>97236973668</phone>
      <email>orie@tasmc.health.gov.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <study_first_submitted>February 21, 2011</study_first_submitted>
  <study_first_submitted_qc>February 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2011</study_first_posted>
  <last_update_submitted>February 22, 2011</last_update_submitted>
  <last_update_submitted_qc>February 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 23, 2011</last_update_posted>
  <responsible_party>
    <name_title>Prof Ori Elkayam</name_title>
    <organization>Department of Rheumatology. Tel Aviv Medical Center</organization>
  </responsible_party>
  <keyword>rheumatoid pertussis tetanus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Whooping Cough</mesh_term>
    <mesh_term>Tetanus</mesh_term>
    <mesh_term>Diphtheria</mesh_term>
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

